Diligence memo · auto-generated · as of July 2, 2026
X4 Pharmaceuticals, Inc
X4 Pharmaceuticals, Inc looks over-valued against its niche peers and is active on financing cadence.
Businessfiled
X4 Pharmaceuticals, Inc operates in Biotechnology, based in BOSTON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
X4 Pharmaceuticals, Inc has raised $320M in disclosed capital across 10 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $85M on 2025-08-13.
Most recent recorded round closed around 2025-08-13.
Valuation (modeled)modeled
Provath models X4 Pharmaceuticals, Inc at approximately $495M (range $263M–$646M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.57× the median modeled value of Series C Biotechnology companies in 2025–2027 (58 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 16 months.
Last raise 11 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 1.3× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 99% of Biotechnology peers (4293 compared).
Modeled value ranks above 83% of those peers.
Closest niche peers: Newleos Therapeutics, Inc., Biolinq Inc, Atsena Therapeutics, Inc., Galvanize Therapeutics, Inc., Endless Corp.
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.